流感毒株已发生变化

Core Viewpoint - The article discusses the anticipated flu season in China, highlighting the expected peak in December and January, along with the current trends in flu virus strains and the availability of antiviral medications [3][4]. Group 1: Flu Season Forecast - The peak of the flu season in China is expected to occur in mid to late December and early January [3]. - Shanghai has reported a rising positive detection rate for flu, indicating the onset of the flu epidemic season [3]. Group 2: Virus Strain Variations - The dominant flu strain in Shanghai has shifted from H1N1 in the first half of the year to H3N2 in the latter half [3]. - Current strains remain highly sensitive to existing antiviral medications, including neuraminidase inhibitors and polymerase inhibitors [3]. Group 3: Antiviral Drug Availability - Hospitals in Shanghai have sufficient supplies of medications to combat respiratory infections, including azithromycin for mycoplasma infections [3]. - The price of the antiviral drug Marbalozav (Sufuda) remains stable at approximately 200 yuan for a 40mg tablet, with children's formulations priced around 250 yuan [4]. Group 4: New Domestic Antiviral Drugs - Two new domestic antiviral drugs, Masurazav (Yisuda) and Masilozav (Jikeshou), have been approved, both requiring only a single dose for treatment [4]. - The prices for these new drugs are lower than Marbalozav, with Jikeshou priced at about 160 yuan for a 40mg tablet and Yisuda at 200 yuan for two 20mg tablets [4]. Group 5: Resistance Issues - Clinical studies indicate low resistance rates for the new antiviral drugs, with mutation rates for H1N1 and H3N2 strains at 0.7% and 0.9% respectively, suggesting a low risk of resistance [4].